Dr. Liam Smyth, a consultant haematologist at St. Vincent’s University Hospital (SVUH), is contributing to advancements in the treatment of blood cancers through his work in malignant haematology and immunotherapies.

A Foundation Rooted in Excellence

Dr. Smyth graduated with his medical degree from Trinity College Dublin in 2008 and completed specialist training in haematology by 2016. His expertise was further refined through a prestigious clinical fellowship in malignant haematology and lymphoma immunotherapy at Sunnybrook Health Sciences Centre and the University of Toronto. Dr Smyth established the Haematology Research Group and remains an active member.

Research & Impact

Dr. Smyth has contributed to several pivotal studies in haematology, particularly focusing on diffuse large B-cell lymphoma (DLBCL). His research has explored the impact of immunotherapy and adjunctive agents such as statins on patient outcomes. Among his key contributions is a widely cited study on how shorter diagnosis-to-treatment intervals influence survival in DLBCL, published in the Journal of the National Comprehensive Cancer Network (JNCCN).

Leading a New Era of Clinical Trials at SVUH

As part of a broader research effort, Dr. Smyth supports the growing haematology clinical trials program at SVUH. In partnership with the UCD Cancer Trials Cluster, the hospital’s Haematology Research Group has increased exponentially its clinical research portfolio in the last year.

Current and upcoming trials at SVUH are exploring targeted therapies, immunotherapies, and novel approaches to blood cancer treatment. These studies contribute to ongoing national and international efforts to improve care options and outcomes for patients living with haematological conditions.